<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>57</patient-age><report-id>US-VERTEX PHARMACEUTICALS INC.-AE-2011-005540</report-id><gender>female</gender><reactions><reaction>Depression</reaction><reaction>SHORTNESS OF BREATH</reaction><reaction>Anxiety</reaction><reaction>BODY ACHES</reaction><reaction>Weight loss of 15 pounds</reaction><reaction>CONSTIPATION</reaction><reaction>thirst</reaction><reaction>gassy</reaction><reaction>bloated stomach</reaction><reaction>FATIGUE</reaction><reaction>Anemia</reaction><reaction>Nausea</reaction><reaction>relapse of HCV</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>VX-950 (Telaprevir)</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PEGASYS</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>RIBAPAK</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Hepatitis C</indication></indications><outcomes/><country>United States</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>uspader</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>30757_111</messagenumb>
		<messagesenderidentifier>VERTEXP2</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151832</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>US-VERTEX PHARMACEUTICALS INC.-AE-2011-005540</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="2">No</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2011-12-21</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-21</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-Vertex Pharmaceuticals Inc.-AE-2011-005540</companynumb>
		<duplicate>1</duplicate>
		<medicallyconfirm>2</medicallyconfirm>
		<reportduplicate>
			<duplicatesource>Vertex Pharmaceuticals Inc.</duplicatesource>
			<duplicatenumb>US-Vertex Pharmaceuticals Inc.-AE-2011-005540</duplicatenumb>
		</reportduplicate>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
			<studyname>Solicited Program</studyname>
			<sponsorstudynumb>Solicited - CVS Caremark</sponsorstudynumb>
			<observestudytype>3</observestudytype>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>US</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>VERTEXP2</senderorganization>
			<senderdepartment>Global Patient Safety</senderdepartment>
			<sendertitle>Mr.</sendertitle>
			<sendergivename>Sean</sendergivename>
			<senderfamilyname>Darcy</senderfamilyname>
			<senderstreetaddress>130 Waverly Street</senderstreetaddress>
			<sendercity>Cambridge</sendercity>
			<senderstate>MA</senderstate>
			<senderpostcode>02139</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<senderemailaddress>VRTXGPS_SubmissionTracking@vrtx.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>Office of Surveillence and Epidemiology</receiverdepartment>
			<receivertitle>Mr.</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receiverfax>3019183134</receiverfax>
			<receiveremailaddress>roger.goetsch@fda.hhs.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>UNKNOWN</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19540112</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hepatitis C</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Depression</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Depression</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Depression</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>SHORTNESS OF BREATH</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Shortness of breath</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dyspnoea</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20111210</reactionstartdate>
				<reactionfirsttime>2</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Anxiety</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Anxiety</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Anxiety</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>BODY ACHES</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Ache</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Pain</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20111215</reactionstartdate>
				<reactionfirsttime>7</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Weight loss of 15 pounds</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Weight loss</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Weight decreased</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>CONSTIPATION</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Constipation</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Constipation</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20111215</reactionstartdate>
				<reactionfirsttime>7</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>thirst</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Thirst</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Thirst</reactionmeddrapt>
			</reaction>
			<reaction>
				<primarysourcereaction>gassy</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Gas</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Flatulence</reactionmeddrapt>
			</reaction>
			<reaction>
				<primarysourcereaction>bloated stomach</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Abdominal bloating</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Abdominal distension</reactionmeddrapt>
			</reaction>
			<reaction>
				<primarysourcereaction>FATIGUE</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Fatigue</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Fatigue</reactionmeddrapt>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20111210</reactionstartdate>
				<reactionfirsttime>2</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Anemia</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Anemia</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Anaemia</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Nausea</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Nausea</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Nausea</reactionmeddrapt>
				<reactionoutcome code="3">not recovered/not resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>relapse of HCV</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Drug ineffective</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Drug ineffective</reactionmeddrapt>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>VX-950 (Telaprevir)</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>201917</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Vertex Pharmaceuticals Inc.</drugauthorizationholder>
				<drugstructuredosagenumb>750</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>750 mg, tid</drugdosagetext>
				<drugdosageform normalized="tablet">Tablet</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-12-08</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-03-01</drugenddate>
				<drugtreatmentduration>85</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>VX-950</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal distension</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Abdominal distension</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anaemia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anaemia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anxiety</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Anxiety</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Constipation</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Constipation</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Depression</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Depression</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Drug ineffective</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fatigue</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Fatigue</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Flatulence</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Flatulence</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nausea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Nausea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Thirst</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Thirst</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Weight decreased</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Related</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Weight decreased</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Not Reported</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>PEGASYS</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugstructuredosagenumb>180</drugstructuredosagenumb>
				<drugstructuredosageunit code="004">micrograms</drugstructuredosageunit>
				<drugdosagetext>180 습g, qw</drugdosagetext>
				<drugadministrationroute code="058">Subcutaneous</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-12-08</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-12-08</drugenddate>
				<drugtreatmentduration>367</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>PEGINTERFERON ALFA-2A</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>RIBAPAK</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>400 mg, bid</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hepatitis C</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-12-08</drugstartdate>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-12-08</drugenddate>
				<drugtreatmentduration>367</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>RIBAVIRIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>RIBAPAK</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugstructuredosagenumb>600</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>600 mg, qd</drugdosagetext>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>RIBAVIRIN</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>A non serious, solicited report <Semaphore x="1870759" class="Disease or Finding" value="Dyspnea" score="1.00" ID="C2998">of <Semaphore x="2918626" class="MedDRA LLT" value="Dyspnoea" score="1.00" ID="10013968">SHORTNESS OF BREATH</Semaphore></Semaphore>, <Semaphore x="1610517" class="AnatomicStructure" value="Body" score="1.00" ID="C13041">BODY </Semaphore>ACHES, <Semaphore x="2004177" class="Procedure" value="Have Constipation" score="1.00" ID="C104299"><Semaphore x="2879571" class="MedDRA LLT" value="Constipation" score="1.00" ID="10010774">CONSTIPATION </Semaphore>and <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">FATIGUE </Semaphore>has </Semaphore>been received from a consumer in the USA concerning a <Semaphore x="1387834" class="Patient Age" value="58" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="58" score="1.00" ID="">58 </Semaphore>year old </Semaphore>female patient, participating in monitored <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>program, subsequent to dosing with <Semaphore x="703687" class="Medicine" value="Incivek" score="0.87" ID="195080">INCIVEK </Semaphore>(<Semaphore x="1250953" class="Medicine" value="telaprevir" score="0.93" ID="195078">telaprevir</Semaphore>).Concomitant medications for this patient included <Semaphore x="1133532" class="Medicine" value="Ribavirin" score="0.93" ID="297021">ribavirin </Semaphore>and peg interferon.No past medical history was provided.The patient received <Semaphore x="703658" class="Medicine - Incivek - Dose" value="750mg" score="0.49" ID=""><Semaphore x="703687" class="Medicine" value="Incivek" score="0.87" ID="195080">Incivek </Semaphore>(<Semaphore x="1250924" class="Medicine - telaprevir - Dose" value="750mg" score="0.49" ID=""><Semaphore x="1250953" class="Medicine" value="telaprevir" score="0.93" ID="195078">telaprevir</Semaphore>) (<Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">oral</Semaphore>, <Semaphore x="3022188097568769" class="Medicine - Incivek - Dose" value="750mg" score="0.49" ID="">750mg </Semaphore></Semaphore></Semaphore>
    <Semaphore x="5372737799323649" class="Medicine - telaprevir - Frequency" value="three" score="0.49" ID="">three </Semaphore>times a day) starting from 08-Dec 2011 for <Semaphore x="2020151" class="Disease or Finding" value="Hepatitis C Infection" score="1.00" ID="C3098">Hepatitis C</Semaphore>. The patient received 2 days of <Semaphore x="703687" class="Medicine" value="Incivek" score="0.87" ID="195080">Incivek </Semaphore>(<Semaphore x="1250953" class="Medicine" value="telaprevir" score="0.93" ID="195078">telaprevir</Semaphore>) <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>before the onset of the events.On 10-Dec 2011, the patient experienced <Semaphore x="1870759" class="Disease or Finding" value="Dyspnea" score="1.00" ID="C2998">shortness of breath </Semaphore>and <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue</Semaphore>. On 15-Dec 2011, the patient experienced <Semaphore x="1610517" class="AnatomicStructure" value="Body" score="1.00" ID="C13041">body </Semaphore><Semaphore x="1412208" class="Disease or Finding" value="Ache" score="1.00" ID="C86024">aches </Semaphore>and <Semaphore x="1810939" class="Procedure" value="Constipation at its Worst" score="1.00" ID="C105544">constipation</Semaphore>. The HCV triple<Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>was <Semaphore x="2149581" class="Procedure" value="Maintenance Therapy" score="1.00" ID="C15688">maintained</Semaphore>At the time of this report, the events <Semaphore x="1870759" class="Disease or Finding" value="Dyspnea" score="1.00" ID="C2998">of <Semaphore x="2918626" class="MedDRA LLT" value="Dyspnoea" score="1.00" ID="10013968">shortness of breath</Semaphore></Semaphore>, <Semaphore x="1610517" class="AnatomicStructure" value="Body" score="1.00" ID="C13041">body </Semaphore><Semaphore x="1412208" class="Disease or Finding" value="Ache" score="1.00" ID="C86024">aches</Semaphore>, <Semaphore x="1810939" class="Procedure" value="Constipation at its Worst" score="1.00" ID="C105544">constipation </Semaphore>and <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue </Semaphore>were ongoingNon serious events of <Semaphore x="2918626" class="MedDRA LLT" value="Dyspnoea" score="1.00" ID="10013968">dyspnoea</Semaphore>, <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>and <Semaphore x="1810939" class="Procedure" value="Constipation at its Worst" score="1.00" ID="C105544">constipation </Semaphore>are considered unexpected while <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue </Semaphore>is expected for <Semaphore x="1250953" class="Medicine" value="telaprevir" score="0.93" ID="195078">telaprevir</Semaphore>. Contributing factors include <Semaphore x="1805680" class="Procedure" value="Concomitant Therapy" score="1.00" ID="C53630">concomitant therapy </Semaphore>with peginterferon and <Semaphore x="1133532" class="Medicine" value="Ribavirin" score="0.93" ID="297021">ribavirin </Semaphore>which have been associated with <Semaphore x="1870759" class="Disease or Finding" value="Dyspnea" score="1.00" ID="C2998">dyspnea</Semaphore>, <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain</Semaphore>, and <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue</Semaphore>.Non serious follow up was received on 29-Nov 2012: New AE terms reported were <Semaphore x="2900421" class="MedDRA LLT" value="Depression" score="1.00" ID="10012378"><Semaphore x="1842410" class="Procedure" value="Depression After Stopping Dexamethasone" score="1.00" ID="C113456">DEPRESSION</Semaphore>, <Semaphore x="1534652" class="Disease or Finding" value="Anxiety Disorder" score="1.00" ID="C2878">ANXIETY</Semaphore></Semaphore>, <Semaphore x="3320348" class="MedDRA LLT" value="Weight decreased" score="1.00" ID="10047895"><Semaphore x="2697990" class="Disease or Finding" value="Weight Loss" score="1.00" ID="C3445">WEIGHT LOSS </Semaphore>OF </Semaphore>15 POUNDS, <Semaphore x="1524787" class="Disease or Finding" value="Anemia" score="1.00" ID="C2869">ANEMIA </Semaphore>and <Semaphore x="2262749" class="Disease or Finding" value="Nausea" score="1.00" ID="C3258">NAUSEA</Semaphore>. It was reported that the patient was still on dual <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>with <Semaphore x="1133532" class="Medicine" value="Ribavirin" score="0.93" ID="297021">ribavirin </Semaphore>and peginterferon and her treating <Semaphore x="2398439" class="Occupation" value="Physician" score="1.00" ID="C25741">physician </Semaphore>planned to stop it at 1 year of <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment</Semaphore>. The patient was treated for the events of <Semaphore x="2900421" class="MedDRA LLT" value="Depression" score="1.00" ID="10012378"><Semaphore x="1842410" class="Procedure" value="Depression After Stopping Dexamethasone" score="1.00" ID="C113456">depression </Semaphore>and <Semaphore x="1534652" class="Disease or Finding" value="Anxiety Disorder" score="1.00" ID="C2878">anxiety </Semaphore></Semaphore>with some unspecified <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment</Semaphore>, which had <Semaphore x="1550141" class="Procedure" value="Assisted Labor" score="1.00" ID="C92738">helped </Semaphore>her. The patient was on <Semaphore x="535266" class="Medicine" value="Epoetin Alfa" score="0.49" ID="190969">epoetin alfa </Semaphore>for the event of anmeia and her <Semaphore x="1133503" class="Medicine - Ribavirin - Dose" value="600 mg" score="0.49" ID=""><Semaphore x="1133532" class="Medicine" value="Ribavirin" score="0.93" ID="297021">ribavirin </Semaphore>dose was <Semaphore x="4868358314917889" class="Medicine - Ribavirin - Dose" value="600 mg" score="0.49" ID="">600 mg </Semaphore></Semaphore>once daily.</narrativeincludeclinical>
				<sendercomment>Non serious events of depression, dyspnoea, anxiety, pain, weight decreased,constipation,thirst,flatulence and abdominal distension are considered unexpected while fatigue,anaemia,nausea and drug ineffective are expected for telaprevir. The concomitant drugs peg-interferon and ribavirin could be the contributory for the reported events while ribavirin for weight decreased and anaemia as well. Dyspnoea and fatigue are likely symptomatic manifestations of the anaemia. Patient is on epoetin alfa.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>